Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 4/2010

01-03-2010 | Original Article

Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam.

Authors: Hironori Iwasaki, Takafumi Okabe, Kensaku Takara, Takayoshi Toda, Masayuki Shimatani, Hirosuke Oku

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2010

Login to get access

Abstract

Purpose

To develop a novel anti-cancer drug of low side effect against lung adenocarcinoma, the authors screened the bioresources of Okinawa Island, Japan. The medicinal plant Toddalia asiatica Lam. contained three benzo[c]phenanthridine derivatives: dihydronitidine (DHN), nitidine (NTD) and demethylnitidine (DMN). Of the three derivatives, DHN had been shown to selectively inhibit the growth of cancer cells in our previous study. Because of similar molecular topology of NTD or DMN to DHN, it can be expected that NTD and DMN also show selective cytotoxicity. The aim of the present study was therefore to examine the selective cytotoxicity of these two compounds in vitro and in vivo.

Methods

Benzo[c]phenanthridine derivatives were isolated from T. asiatica Lam., and their chemical structures were identified by interpretation of NMR and MS spectrum. Of the isolated compounds, NTD and DMN were evaluated for cytotoxicity in vitro or in vivo.

Results

NTD as well as DHN selectively reduced the growth of murine and human lung adenocarcinoma in vitro with selective intracellular accumulation. NTD has also been proven to be highly effective in vivo to inhibit the growth of both murine and human lung adenocarcinoma in a subcutaneous xenograft model without any deteriorating side effect. In contrast, DMN had no selective cytotoxicity suggesting that 8-methoxy group of NTD is the critical structural feature for the selective cytotoxicity.

Conclusions

This study thus proves the effectiveness of benzo[c]phenanthridine derivatives as anti-cancer agent in vivo for the first time, and discusses the mechanisms responsible for the selective cytotoxicity.
Literature
1.
go back to reference Kojima A, Hackett NR, Ohwada A, Crystal RG (1998) In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 101:1789–1796CrossRefPubMed Kojima A, Hackett NR, Ohwada A, Crystal RG (1998) In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest 101:1789–1796CrossRefPubMed
2.
go back to reference Takimoto CH, Wright J, Arbuck SG (1998) Clinical applications of the camptothecins. Biochim Biophys Acta 1400:107–119PubMed Takimoto CH, Wright J, Arbuck SG (1998) Clinical applications of the camptothecins. Biochim Biophys Acta 1400:107–119PubMed
3.
go back to reference Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierre A, Atassi G (2000) Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 6:297–304PubMed Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierre A, Atassi G (2000) Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res 6:297–304PubMed
5.
go back to reference Ancuceanu RV, Istudor V (2004) Pharmacologically active natural compounds for lung cancer. Altern Med Rev 9:402–419PubMed Ancuceanu RV, Istudor V (2004) Pharmacologically active natural compounds for lung cancer. Altern Med Rev 9:402–419PubMed
6.
go back to reference Iwasaki H, Oku H, Takara R, Miyahira H, Hanashiro K, Yoshida Y, Kamada Y, Toyokawa T, Takara K, Inafuku M (2006) The tumor-specific cytotoxicity of dihydronitidine from Toddalia asiatica Lam. Cancer Chemother Pharmacol 58:451–459CrossRefPubMed Iwasaki H, Oku H, Takara R, Miyahira H, Hanashiro K, Yoshida Y, Kamada Y, Toyokawa T, Takara K, Inafuku M (2006) The tumor-specific cytotoxicity of dihydronitidine from Toddalia asiatica Lam. Cancer Chemother Pharmacol 58:451–459CrossRefPubMed
7.
go back to reference Li D, Zhao B, Sim SP, Li TK, Liu A, Liu LF, LaVoie EJ (2003) 8, 9-Methylenedioxybenzo[i]phenanthridines: topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 11:3795–3805CrossRefPubMed Li D, Zhao B, Sim SP, Li TK, Liu A, Liu LF, LaVoie EJ (2003) 8, 9-Methylenedioxybenzo[i]phenanthridines: topoisomerase I-targeting activity and cytotoxicity. Bioorg Med Chem 11:3795–3805CrossRefPubMed
8.
go back to reference Affymetrix I (2002) GeneChip expression analysis technical manual. Affymetrix, Inc., Santa Clara, CA Affymetrix I (2002) GeneChip expression analysis technical manual. Affymetrix, Inc., Santa Clara, CA
9.
go back to reference Wang HK, Morris-Natschke SL, Lee KH (1997) Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Med Res Rev 17:367–425CrossRefPubMed Wang HK, Morris-Natschke SL, Lee KH (1997) Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Med Res Rev 17:367–425CrossRefPubMed
10.
go back to reference Li D, Zhao B, Sim SP, Li TK, Liu A, Liu LF, LaVoie EJ (2003) 2, 3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem 11:521–528CrossRefPubMed Li D, Zhao B, Sim SP, Li TK, Liu A, Liu LF, LaVoie EJ (2003) 2, 3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents. Bioorg Med Chem 11:521–528CrossRefPubMed
11.
go back to reference Makhey D, Li D, Zhao B, Sim SP, Li TK, Liu A, Liu LF, LaVoie EJ (2003) Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents. Bioorg Med Chem 11:1809–1820CrossRefPubMed Makhey D, Li D, Zhao B, Sim SP, Li TK, Liu A, Liu LF, LaVoie EJ (2003) Substituted benzo[i]phenanthridines as mammalian topoisomerase-targeting agents. Bioorg Med Chem 11:1809–1820CrossRefPubMed
12.
go back to reference Sanders MM, Liu AA, Li TK, Wu HY, Desai SD, Mao Y, Rubin EH, LaVoie EJ, Makhey D, Liu LF (1998) Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells. Biochem Pharmacol 56:1157–1166CrossRefPubMed Sanders MM, Liu AA, Li TK, Wu HY, Desai SD, Mao Y, Rubin EH, LaVoie EJ, Makhey D, Liu LF (1998) Selective cytotoxicity of topoisomerase-directed protoberberines against glioblastoma cells. Biochem Pharmacol 56:1157–1166CrossRefPubMed
13.
go back to reference Makhey D, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ (1996) Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem 4:781–791CrossRefPubMed Makhey D, Gatto B, Yu C, Liu A, Liu LF, LaVoie EJ (1996) Coralyne and related compounds as mammalian topoisomerase I and topoisomerase II poisons. Bioorg Med Chem 4:781–791CrossRefPubMed
14.
Metadata
Title
Tumor-selective cytotoxicity of benzo[c]phenanthridine derivatives from Toddalia asiatica Lam.
Authors
Hironori Iwasaki
Takafumi Okabe
Kensaku Takara
Takayoshi Toda
Masayuki Shimatani
Hirosuke Oku
Publication date
01-03-2010
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2010
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-009-1077-7

Other articles of this Issue 4/2010

Cancer Chemotherapy and Pharmacology 4/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine